GlaxoSmithKline Gains Antibody for Type I Diabetes
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 90 (Table of Contents)
Published: 7 Dec-2007
DOI: 10.3833/pdr.v2007.i90.249 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
GlaxoSmithKline and Tolerx entered into license agreement for Tolerx’s otelixizumab (TRX4) monoclonal antibody for treating type I diabetes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
Login Problems
RSS